Literature DB >> 3757401

Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation.

A O Iyun, M S Lennard, G T Tucker, H F Woods.   

Abstract

The role of genetic polymorphism in the oxidative metabolism of metoprolol and debrisoquin was investigated in a population of 138 unrelated Nigerians. The debrisoquin/4-hydroxydebrisoquin 0-8 hour urinary ratio (D/HD) correlated significantly with the metoprolol/alpha-hydroxymetoprolol 0-8 hour urinary ratio (M/HM) (rs = 0.54; P less than 0.001), the metoprolol/H117-04 [4-(2-hydroxy-3-isopropylaminopropoxy)-phenylacetic acid] 0-8 hour urinary ratio (M/H117-04) (rs = 0.42; P less than 0.001), and the plasma metoprolol concentration at 3 hours (rs = 0.48; P less than 0.01). Both the median D/HD and M/HM ratios were significantly higher in this population than in a previously studied population of white British subjects. According to criteria established in studies of white populations, only one subject, later identified as an Indian, would be classified unequivocally as a poor metabolizer of both metoprolol and debrisoquin. All the other subjects were black Africans. Bimodality in the frequency distribution of both the log10 M/HM and D/HD ratios was not apparent. The poor hydroxylation trait may, therefore, be present at a lower frequency than in whites, absent altogether, or obscured by other factors. In ethnic studies of drug metabolism each racial group should be examined separately for evidence of polymorphic metabolism and antimodes should not be extrapolated from one population to another.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3757401     DOI: 10.1038/clpt.1986.195

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  26 in total

1.  Uses and misuses of definitions of genetic polymorphism. A perspective from population pharmacogenetics.

Authors:  T D Arias; L F Jorge; R Barrantes
Journal:  Br J Clin Pharmacol       Date:  1991-01       Impact factor: 4.335

Review 2.  Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.

Authors:  Eleanor Murphy; Francis J McMahon
Journal:  Discov Med       Date:  2013-09       Impact factor: 2.970

Review 3.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population.

Authors:  Y Horai; J Taga; T Ishizaki; K Ishikawa
Journal:  Br J Clin Pharmacol       Date:  1990-01       Impact factor: 4.335

5.  Metabolic ratios of four probes of CYP2D6 in Turkish subjects: a cross-over study.

Authors:  A Bozkurt; N E Basçi; A Işimer; A Sayal; S O Kayaalp
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

6.  An observation on the ethnic uniqueness of the debrisoquine and sparteine antimodes: a study in the Ngawbé Guaymí Amerindians of Panamá.

Authors:  T D Arias; L F Jorge
Journal:  Br J Clin Pharmacol       Date:  1989-10       Impact factor: 4.335

7.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

8.  Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians.

Authors:  H F al-Hadidi; Y M Irshaid; N M Rawashdeh
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  N-acetylation phenotyping with dapsone in a mainland Chinese population.

Authors:  Y Horai; H H Zhou; L M Zhang; T Ishizaki
Journal:  Br J Clin Pharmacol       Date:  1988-01       Impact factor: 4.335

10.  Genetic basis for a lower prevalence of deficient CYP2D6 oxidative drug metabolism phenotypes in black Americans.

Authors:  W E Evans; M V Relling; A Rahman; H L McLeod; E P Scott; J S Lin
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.